ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial
ICON provided both decentralised and on-site clinical trial services to the Pfizer BioNTech COVID-19 vaccine programme.
ICON Releases First Environmental, Social and Governance Report
ICON announces the release of its first Environmental, Social and Governance (ESG) Report.
ICON plc to present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference
ICON plc to present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference
ICON Reports Third Quarter 2020 Results
Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and 13.1% increase on Quarter 2 2020.
BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
To help strengthen US emergency preparedness and response. ICON continues as part of BARDA’s exclusive Medical Countermeasures Clinical Studies Network.
ICON wins Best CRO at the Vaccine Industry Excellence Awards
This marks the third time ICON plc has won the award for excellence in vaccine research. The company has been named as a finalist every year since 2011.
ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials.
ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference
Thursday, September 10, 2020 at 09.05am EDT.
Forbes names ICON in list of Best Employers in America for Women
ICON recognised as top employer for women in anonymous survey of 75,000 employees.
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
Dublin, Ireland, July 22, 2020